Company intelligence / Profile preview

Shanghai Baiyiyuan Bioengineering

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Baiyiyuan Bioengineering's lead product is a decellularized extracellular matrix implant—a collagen-based injectable for medical aesthetics and tissue repair. The product is currently in registrational clinical trials in China and has recently been exclusively out-licensed to CMS Skinhealth for commercialization in Greater China. Early results suggest the product enables safe and natural tissue repair and rejuvenation.[5]

Therapeutic areas: Dermatology
Modalities: Decellularized extracellular matrix implantCollagen-based biomaterialMedical device
Industry: Implantable Medical Devices

Partnerships

CMS Skinhealth (exclusive licensee for Greater China)[5]

Beyond the preview

Go deeper on Shanghai Baiyiyuan Bioengineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Baiyiyuan Bioengineering.

Explore the full profile